Leishmaniasis: Therapeutic options in the pediatric population
Keywords:
Leishmaniasis - Pediatric population - Leishmania species - treatment in childrenAbstract
Leishmaniasis is a chronic parasitic disease endemic in many parts of the world. The variability of strains, their clinic and response to treatment has led to their classification into two major groups: New World leishmaniasis and Old World leishmaniasis. According to this, the recommendations regarding management and follow-up vary. In this review, emphasis is placed on leishmaniasis in our environment, reviewing therapeutic options and possibilities mainly in the pediatric population.
References
1. Haldar, A.; Sen, P., Roy, S. Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions. Molecular Biology International, 2011. Doi:10.4061/2011/571242
2. Jaramillo-Antillón, O.; Espinoza-Aguerre, A.; Lobo-Philp, R. Estado actual de la leishmaniasis en Costa Rica. Acta Médica Costarricense; 51(3):2009.
3. Oliviera, L.; Schubach, A.; Martins, M.; et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica 118(2011): 87-96.
4. Mohebali, M.; Fotouhi, A.; Hooshmand, B.; et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis by a randomized clinical trial in Iran. Acta Tropica 103(2007): 33-40.
5. Layegh, P.; Rahsepar, S.; Ali, A. Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults. Am J Trop Med Hyg, 84(4), 2011: 539-542.
6. Munir, A.; Janjua, S.; Hussain, I. Clinical Efficacy of Intramuscular Meglumine Antimoniate Alone and in Combination with Intralesional Meglumine Antimoniate in the Treatment of Old World Cutaneous Leishmanisis. Acta Dermatovenerol Croat 2008; 16(2):60-64.
7. Dorlo, T.; Balasegaram, M.; Beijen, J.; et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemaother. doi:10.1093/jac/dks275
8. Mitropoulos, P.; Konidas, P.; Durkin.Konidas, M. New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010;63:309-22.
9. Rubiano, P.; Miranda, M.; Muvdi, S.; et al. Noninferiority of Miltefosine versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children. JID 2012:205.
10. Vélez, I.; López, L.; Sánchez, X.; et al. Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis. Am J Trop Med Hyg 83(2), 2010: 351-356.
11. Tiuman, T.; Santos, A.; Ueda-Nakamura, T.; et al. Recent advances in leishmaniasis treatment. International Journal of Infectious Diseases 15 (2011):e525-e532.
12. Soto, J.; Rea, J.; Balderrama, M.; et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-1.
13. Prospecto de Glucantime®, Sanofi- Aventis. Junio 2012
14. Nunes, E.; De Oliveira, J.; Talgari, C.; et al. Efficacy and safety of a single dose pentamidine (7mg/kg) fos patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study. An Bras Dermatol. 2015;90(6):807-13.
15. Soto, J.; Arana, B.A.; Toledo, J.; et al. Miltefosine for New World Cutaneous Leishmaniasis. Clinical Infectious Diseases 2004;38:1266-72.
16. Mesa-Arango, A.; Scorzonii, L; Zaragoza, O. It only takes one to do many Jobs: AMphotericin B as antifungal and immunomodulatory drug. Front Microbiol 2012;3(286):1-10.
17. Markle, W.; Makhoul, K. Cutaneous Leishmaniasis: Recognition and Treatment. Am Fam Physician 2004;69:455-60.
18. Blanco, V.; Cossio, A.; Martinez, J.; Gore, N. Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. Am J Trop Med Hyg 2013;89(2):359-364.
2. Jaramillo-Antillón, O.; Espinoza-Aguerre, A.; Lobo-Philp, R. Estado actual de la leishmaniasis en Costa Rica. Acta Médica Costarricense; 51(3):2009.
3. Oliviera, L.; Schubach, A.; Martins, M.; et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Tropica 118(2011): 87-96.
4. Mohebali, M.; Fotouhi, A.; Hooshmand, B.; et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis by a randomized clinical trial in Iran. Acta Tropica 103(2007): 33-40.
5. Layegh, P.; Rahsepar, S.; Ali, A. Systemic Meglumine Antimoniate in Acute Cutaneous Leishmaniasis: Children versus Adults. Am J Trop Med Hyg, 84(4), 2011: 539-542.
6. Munir, A.; Janjua, S.; Hussain, I. Clinical Efficacy of Intramuscular Meglumine Antimoniate Alone and in Combination with Intralesional Meglumine Antimoniate in the Treatment of Old World Cutaneous Leishmanisis. Acta Dermatovenerol Croat 2008; 16(2):60-64.
7. Dorlo, T.; Balasegaram, M.; Beijen, J.; et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemaother. doi:10.1093/jac/dks275
8. Mitropoulos, P.; Konidas, P.; Durkin.Konidas, M. New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatment. J Am Acad Dermatol 2010;63:309-22.
9. Rubiano, P.; Miranda, M.; Muvdi, S.; et al. Noninferiority of Miltefosine versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children. JID 2012:205.
10. Vélez, I.; López, L.; Sánchez, X.; et al. Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis. Am J Trop Med Hyg 83(2), 2010: 351-356.
11. Tiuman, T.; Santos, A.; Ueda-Nakamura, T.; et al. Recent advances in leishmaniasis treatment. International Journal of Infectious Diseases 15 (2011):e525-e532.
12. Soto, J.; Rea, J.; Balderrama, M.; et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008;78:210-1.
13. Prospecto de Glucantime®, Sanofi- Aventis. Junio 2012
14. Nunes, E.; De Oliveira, J.; Talgari, C.; et al. Efficacy and safety of a single dose pentamidine (7mg/kg) fos patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study. An Bras Dermatol. 2015;90(6):807-13.
15. Soto, J.; Arana, B.A.; Toledo, J.; et al. Miltefosine for New World Cutaneous Leishmaniasis. Clinical Infectious Diseases 2004;38:1266-72.
16. Mesa-Arango, A.; Scorzonii, L; Zaragoza, O. It only takes one to do many Jobs: AMphotericin B as antifungal and immunomodulatory drug. Front Microbiol 2012;3(286):1-10.
17. Markle, W.; Makhoul, K. Cutaneous Leishmaniasis: Recognition and Treatment. Am Fam Physician 2004;69:455-60.
18. Blanco, V.; Cossio, A.; Martinez, J.; Gore, N. Clinical and Epidemiologic Profile of Cutaneous Leishmaniasis in Colombian Children: Considerations for Local Treatment. Am J Trop Med Hyg 2013;89(2):359-364.
Downloads
Published
2020-11-14
Issue
Section
Literature review
License
The intellectual property of accepted works belongs to their authors, however access to them is totally open and free, so they can be reproduced totally or partially with the only limitation of recognizing the authorship and the source of publication (Revista Medicina Legal de Costa Rica), as long as said exploitation does not have commercial character.
How to Cite
Leishmaniasis: Therapeutic options in the pediatric population. (2020). Medicina Legal De Costa Rica, 35(1). https://www.binasss.sa.cr/ojssalud/index.php/mlcr/article/view/86
